Welcome to our dedicated page for KANE BIOTECH ORD news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on KANE BIOTECH ORD stock.
Kane Biotech Inc. (KNBIF) is a biotechnology company dedicated to researching, developing, and commercializing technologies and products that prevent and eliminate microbial biofilms. With a robust portfolio of intellectual property and products like StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™, the company is at the forefront of biofilm research. Recently, Kane Biotech announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel. The company is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
Kane Biotech Inc. is set to enhance its investor relations at the 10th Annual Whistler 2021 Capital Conference from July 9-11, 2021. CEO Marc Edwards will meet investors to discuss progress in animal health, OTC consumer goods, and wound care. Key highlights include:
- $2.7 million funding from the US Department of Defense for DispersinB® development.
- Growing partnerships in pet oral care, targeting a $5 billion market.
- 6.2 million warrants exercised, providing crucial cash for investments.
For further details, visit kanebiotech.com.
Kane Biotech has launched a five-part video series titled “2021 Business Update”, starting with Episode 1 - “The Fundamentals”, released on June 16, 2021. This series aims to inform stakeholders about the company's strategies across its three key areas: OTC consumer products, animal health, and wound care. The first episode includes insights from CEO Marc Edwards and Chief Scientific Officer Gordon Guay, focusing on market opportunities and the company's approach to addressing biofilm-related issues. Subsequent episodes will cover innovations in various product lines and funding strategies.
Kane Biotech Inc. announced the approval of key compensation plans at its shareholder meeting on May 26, 2021. The Performance and Restricted Share Unit Plan (PRSU Plan) allows for the issuance of restricted and performance share units to employees and directors, with a cap of 10% of total outstanding shares. Additionally, the Amended and Restated Stock Option Plan reserves a maximum of 10% of common shares for stock options, removing previous aggregation requirements with other share plans. Details are available on SEDAR.
Kane Biotech reported first quarter 2021 financial results, with revenue from product sales at $254,448, down 4% from 2020 due to COVID-related shutdowns. However, sales to other pet retailers increased by approximately 27%. Total revenue grew by 58% compared to the previous quarter. Gross profit decreased 7% to $165,876, while operating expenses dropped 29% to $1,149,611. The company saw a net loss of ($1,010,892), a 26% improvement year-over-year. CEO Marc Edwards expressed optimism about future growth opportunities and partnerships.
Kane Biotech Inc. will release its Q1 2021 financial results on May 27, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss the results and business developments. The company specializes in technologies to prevent and remove microbial biofilms, holding a portfolio of 53 patents and various trademarks. Kane Biotech is listed on TSX-V under the symbol KNE and on OTCQB under KNBIF. Risks include financial instability, reliance on equity financing, and potential impacts from COVID-19.
Kane Biotech Inc. has announced positive results from a significant consumer trial of its DermaKB™ products, conducted from November 2020 to January 2021. Of over 4,500 participants, 1,402 completed questionnaires, revealing that 82% saw symptom improvement after using Detoxifier and Shampoo, with an average 33% reduction in symptom severity from just a 3 oz. sample. Remarkably, 63% of users preferred DermaKB™ over their previous leading dandruff shampoo. This trial highlights the market need for these products, suggesting strong consumer interest and potential growth for the company.
Kane Biotech Inc. (OTCQB: KNBIF) announced the engagement of Dr. Allan Mandelzys as an advisor to its Board of Directors, with a nomination for board directorship at the upcoming Annual and Special Meeting on May 26, 2021. Dr. Mandelzys brings extensive experience in the biotechnology sector, having held key roles in various companies, including Searchlight Pharma and Matrizyme Pharma. His expertise is expected to enhance Kane's strategic growth, especially in addressing challenges like microbial biofilms and antibiotic resistance.
Kane Biotech Inc. (OTCQB:KNBIF) will release its fourth quarter and full year 2020 financial results on March 25, 2021, after market close. The management team will hold a conference call at 4:30 p.m. ET to discuss these results and business developments. The call can be accessed at 1-877-268-9044 (Canada) or 1-706-679-2995 (International), with replay available at 1-404-537-3406. Kane Biotech specializes in biotechnology focused on microbial biofilm solutions and holds a substantial portfolio of intellectual property.
Kane Biotech Inc. (OTCQB: KNBIF) announced that CEO Marc Edwards will present at the Emerging Growth Virtual Conference on March 17-18, 2021. The event will feature discussions and presentations from various leaders in the Biotech and Healthcare sectors. Edwards expressed excitement about sharing the company's growth story, highlighting successes in commercializing products across three markets and securing government funding. Kane Biotech specializes in technologies that prevent and remove microbial biofilms, holding a robust portfolio of intellectual property.
Kane Biotech Inc. (OTCQB: KNBIF) announced that preliminary analysis of efficacy trials for STEM Animal Health's pet oral care additive has successfully met its primary endpoint. This achievement opens the door for two milestone payments from STEM's licensing partners, contingent on positive clinical efficacy data. STEM's products utilize Kane’s patented Coactiv+™ technology aimed at combating plaque and tartar biofilm in pets. The collaboration between Kane and Animalcare Group focuses on advancing biofilm-related treatments in animals.
FAQ
What is the current stock price of KANE BIOTECH ORD (KNBIF)?
What is the market cap of KANE BIOTECH ORD (KNBIF)?
What is Kane Biotech Inc. known for?
What are some of the key products offered by Kane Biotech?
Where is Kane Biotech listed?
What recent achievements has Kane Biotech announced?
Who is the President and CEO of Kane Biotech?
What sets Kane Biotech apart in the biotechnology industry?
How can investors participate in Kane Biotech's growth?
What recent financial results has Kane Biotech shared?
Where can I find more information about Kane Biotech?
What industry does Kane Biotech operate in?
